Frank Aquila Named Dealmaker of the Week by The Am Law Daily

September 3, 2013

On September 3, The Am Law Daily recognized Mr. Aquila as Dealmaker of the Week for his role in Amgen Inc.'s $10.4 billion acquisition of Onyx Pharmaceuticals, Inc. After an earlier offer of $120 per share was turned down by Onyx in June, Amgen succeeded with a $125 per share agreement – the second-largest deal in Amgen's history. “We always knew that the combination of Onyx and Amgen was a great fit, so I always felt the deal would ultimately come together,” said Mr. Aquila. The deal came on the heels of other major transactions in the sector, and Mr. Aquila told Am Law that he “fully expects deal activity to continue at its current pace in the health care sector for the foreseeable future and to improve in other areas in 2014.” Mr. Aquila has been Amgen's regular outside counsel for years, and has advised on every Amgen acquisition since 2005. He began working with Amgen when David Scott joined as general counsel in 2004. "Dave and I have worked together on a variety of deals at a number of different companies for over 20 years," Mr. Aquila told Am Law